Paul M Maciocia

Nov 11, 2024 | nature.com | Kate Cwynarski |Mathieu Ferrari |Paul M Maciocia

AbstractRelapsed/refractory peripheral T cell lymphomas (PTCLs) are aggressive tumors with a poor prognosis. Unlike B cell lymphomas, treatment of PTCL has not benefited from advances in immunotherapy. This is largely due to a lack of suitable target antigens that discriminate malignant from normal T cells, thus avoiding severe immunosuppression consequent to depletion of the entire T cell compartment.